Literature DB >> 29654483

Chinese Experts Consensus on Clinical Application of Naoxintong Capsule ().

Liu Long-Tao1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29654483     DOI： 10.1007/s11655-018-2981-6

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN： 1672-0415            Impact factor:   1.978


× No keyword cloud information.
  10 in total

1.  Protective effect of Naoxintong against cerebral ischemia reperfusion injury in mice.

Authors:  Jing Xue; Xiangjian Zhang; Cong Zhang; Ning Kang; Xiaoxia Liu; Jingying Yu; Nan Zhang; Hong Wang; Lan Zhang; Rong Chen; Lili Cui; Lina Wang; Xiaolu Wang
Journal:  J Ethnopharmacol       Date:  2016-02-20       Impact factor: 4.360

2.  NaoXinTong Inhibits the Advanced Atherosclerosis and Enhances the Plaque Stability in Apolipoprotein E Deficient Mice.

Authors:  Xiaoxiao Yang; Lei Sun; Yan Li; Chuanrui Ma; Jie Yang; Wenwen Zhang; Buchang Zhao; Lifu Jia; Yajun Duan; Jihong Han; Xiaoju Li; Yuanli Chen
Journal:  J Cardiovasc Pharmacol       Date:  2016-03       Impact factor: 3.105

3.  Efficacy of dual antiplatelet therapy combined with Naoxintong capsules [see text] following coronary microembolization induced by homologous microthrombi in rats.

Authors:  Huan Wang; Wen-juan Zhong; Ming-wei Huang; Xiao-ying Wu; Hui Chen
Journal:  Chin J Integr Med       Date:  2011-12-03       Impact factor: 1.978

4.  A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism.

Authors:  Hui Chen; Xiao-Ying Wu; Hong-Xia Wu; Huan Wang
Journal:  Chin J Integr Med       Date:  2014-11-27       Impact factor: 1.978

5.  Metabolomics study on the effects of Buchang Naoxintong capsules for treating cerebral ischemia in rats using UPLC-Q/TOF-MS.

Authors:  Mengting Liu; Xin Liu; Hongping Wang; Hongbin Xiao; Fang Jing; Liying Tang; Defeng Li; Yi Zhang; Hongwei Wu; Hongjun Yang
Journal:  J Ethnopharmacol       Date:  2016-01-19       Impact factor: 4.360

6.  Comparison of Adjunctive Naoxintong versus Clopidogrel in Volunteers with the CYP2C19*2 Gene Mutation Accompanied with Qi Deficiency and Blood Stasis Constitution.

Authors:  Hui Chen; Guangwei Yu; Hong Sun; Xiaoying Wu; Huan Wang
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-01       Impact factor: 2.629

7.  In Vitro Assessment of Cytochrome P450 2C19 Potential of Naoxintong.

Authors:  Hui Chen; Ya Zhang; Xiaoying Wu; Candong Li; Huan Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-16       Impact factor: 2.629

8.  Naoxintong attenuates Ischaemia/reperfusion Injury through inhibiting NLRP3 inflammasome activation.

Authors:  Yaqiong Wang; Xiaoxiang Yan; Shouling Mi; Zhang Li; Yuexiang Wang; Hong Zhu; Xiaolei Sun; Buchang Zhao; Chao Zhao; Yunzeng Zou; Kai Hu; Xiaoqiang Ding; Aijun Sun; Junbo Ge
Journal:  J Cell Mol Med       Date:  2016-10-26       Impact factor: 5.310

9.  Up-Regulation of CYP2C19 Expression by BuChang NaoXinTong via PXR Activation in HepG2 Cells.

Authors:  Hong Sun; Xiao-Ya Lou; Xiao-Ying Wu; Huan Wang; Qiang Qu; Shen-Lan Tan; Jun-Shan Ruan; Jian Qu; Hui Chen
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

10.  Naoxintong/PPARα Signaling Inhibits H9c2 Cell Apoptosis and Autophagy in Response to Oxidative Stress.

Authors:  Huimin Xu; Jianhua Jin; Lu Chen; Chunxiao Li; Qinggang Xu; Juanjuan Shi; Buchang Zhao; Yongzhong Hou; Hong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2016-09-07       Impact factor: 2.629
  10 in total
  4 in total

1.  Integrated metabolomics and gut microbiome to the effects and mechanisms of naoxintong capsule on type 2 diabetes in rats.

Authors:  Zenghao Yan; Hao Wu; Haokui Zhou; Shuo Chen; Yan He; Weijian Zhang; Taobin Chen; Hongliang Yao; Weiwei Su
Journal:  Sci Rep       Date:  2020-07-02       Impact factor: 4.379

2.  Experimental Evidence of Buyang Huanwu Decoction and Related Modern Preparations (Naoxintong Capsule and Yangyin Tongnao Granule) in Treating Cerebral Ischemia: Intestinal Microorganisms and Transcriptomics in Rats.

Authors:  Junjun Yin; Jiehong Yang; Buchang Zhao; Chao Zhao; Wei Fu; Yu He; Miaolin Zeng; Yuting Yang; Xiaoyu Wei; Zhishan Ding; Jingxian Bai; Haitong Wan; Huifen Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-21       Impact factor: 2.650

3.  Specific DNA identification of Pheretima in the Naoxintong capsule.

Authors:  Xiaoxiao Zhu; Hoi-Yan Wu; Pang-Chui Shaw; Wei Peng; Weiwei Su
Journal:  Chin Med       Date:  2019-09-30       Impact factor: 5.455

4.  Comparison of Buyang Huanwu granules and Naoxintong capsules in the treatment of stable angina pectoris: rationale and design of a randomized, blinded, multicentre clinical trial.

Authors:  Yu Wang; Yuhan Xu; Ling Zhang; Shuwei Huang; Liping Dou; Jiehong Yang; Wei Fu; Peng Zhou; Haitong Wan
Journal:  Trials       Date:  2022-01-21       Impact factor: 2.279
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.